Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma

Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period

(2019) Zhan Shi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Rituximab in the treatment of immune thrombocytopenia: what role for this agent in 2019?

(2019) Elisa Lucchini et al.   HAEMATOLOGICA

Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?

(2019) Sang-Gon Park   KOREAN JOURNAL OF INTERNAL MEDICINE

Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center

(2019) Kaitlyn E. Kowalski et al.   Clinical Lymphoma Myeloma & Leukemia

Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma: A Single Institution Experience

(2019) Dilan A. Patel et al.   Clinical Lymphoma Myeloma & Leukemia

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas

(2017) Tatsuya Hayama et al.   International Journal of Clinical Pharmacy

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

(2017) Kyoung Min Cho et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Rituximab for nephrotic syndrome in children

(2016) Kazumoto Iijima et al.   Clinical and Experimental Nephrology

Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study

(2015) Stefan Norin et al.   LEUKEMIA RESEARCH

The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital

(2014) Jae-Woo Jung et al.   ONCOLOGY

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

(2012) Norbert Schmitz et al.   LANCET ONCOLOGY

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

(2012) Junshik Hong et al.   SUPPORTIVE CARE IN CANCER

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

Prognostic Value of Platelet Count in Diffuse Large B-Cell Lymphoma

(2011) Ling-Ping Chen et al.   Clinical Lymphoma Myeloma & Leukemia

First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial

(2011) Umberto Vitolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy

(2011) Liang Wang et al.   MEDICAL ONCOLOGY

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

(2008) C Buske et al.   LEUKEMIA